I am -- That's why FDA has told NWBO not to bother filing a commercial application. Nobody else really matters. UK is not a financially viable market for NWBO to survive. Only U.S. market provides the scale and pricing for oncology developers to become financially successful. But it would take a compliant P3 trial.
Approval in UK won't make NWBO successful. Just continue as a Zombie Biotech.
Market Data 
Markets 
AI
